BPGbio

BPGbio is a clinical-stage biopharmaceutical company focused on developing mitochondrial-targeted therapies for patients. The company’s approach is grounded in advancing therapeutics that restore cellular energy regulation and address mitochondrial dysfunction, a central driver of disease across multiple high-burden indications.

BPGbio’s lead clinical candidate, BPM31510, is a potential first-in-class mitochondrial metabolic modulator currently in clinical development for Primary CoQ10 Deficiency (PCQD) and Glioblastoma. The asset has also completed a phase I trial in Epidermolysis Bullosa (EB). The company is currently exploring the potential of BPM31510 in small cell carcinoma (SCC), pancreatic cancers, and sarcopenia.